IMAX IMAX CORP

FY2025 10-K
Filed: Feb 25, 2026
Health Care
Photographic Equipment & SuppliesSEC EDGAR

IMAX CORP (IMAX) filed its fiscal year 2025 10-K annual report with the SEC on Feb 25, 2026. This page provides AI-powered analysis of the filing, including business overview, management discussion, risk factors, and key financial metrics from XBRL data.

AI Filing Analysis
FY2025 10-K

Business Overview

  • Core business: Proprietary IMAX Film Remastering enhances films for exclusive IMAX format distribution, earning ~12.5% global box office revenue
  • New emphasis on local language film releases, reaching 67 films in 2025, generating $405.4M or 32% of total global box office
+3 more insights

Management Discussion & Analysis

  • Film releases 2026: 21 titles released, 30 additional titles announced including IMAX DNA and local language films
  • Other Content Solutions: 75 documentary distribution rights as of Dec 31, 2025, including collaborations with NBA, Grizzly Creek, Beach House Pictures
+3 more insights

Risk Factors

  • Foreign currency risk hedged with $48.4M notional cash flow contracts; $1.7M gain in OCI in 2025 versus $3.5M loss in 2024
  • Geopolitical exposure with $130.2M financing receivables and working capital in CAD, RMB, JPY, EUR; 10% FX move impacts $13.0M fair value
+3 more insights

Financial Summary
XBRL

Revenue

$410M

Net Income

$35M

Gross Margin

60.0%

Operating Margin

20.5%

Net Margin

8.5%

ROE

10.3%

Total Assets

$894M

EPS (Diluted)

$0.63

Operating Cash Flow

$127M

Source: XBRL data from IMAX CORP FY2025 10-K filing on SEC EDGAR. All figures in USD.

Get deeper insights on IMAX CORP

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.

Try Pro free for 1 month!

Enter SX-8KKYTN at checkout

Limited spots available